In a groundbreaking initiative, active-duty US service members suffering from post-traumatic stress disorder (PTSD) are set to participate in MDMA-assisted therapy sessions next year, marking a significant shift in the military’s approach to mental health treatment. Funded by the Department of Defense (DoD), these studies aim to explore the therapeutic potential of psychedelics in helping soldiers process trauma and improve their overall well-being.
A Paradigm Shift in Military Mental Health
The DoD has announced plans for two studies involving 186 soldiers diagnosed with PTSD, with the first sessions expected to commence in 2027. This innovative approach has garnered attention not only from within the military but also from mental health advocates. Sean O’Keefe, the Deputy Under Secretary of War for Personnel and Readiness, is closely monitoring the research developments. In preparation for the upcoming trials, a new cadre of therapists from both the DoD and the Department of Veterans Affairs (VA) will begin training in psychedelic-assisted therapies.
Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies (MAPS), expressed optimism about the potential benefits of this treatment. “Helping people process trauma, whoever they are, is probably better than not,” he noted, highlighting the moral imperative to support those who serve. Doblin’s sentiments resonate with many who view this programme as an opportunity to provide effective treatment for soldiers, enabling them to serve longer and transition back to civilian life without the burdens of unresolved trauma.
Legislative Support and Funding
The funding for these studies was incorporated into the National Defence Authorization Act signed by former President Joe Biden in December 2023. This act was influenced by Republican Congressman Morgan Luttrell, a veteran Navy SEAL who has experienced psychedelic therapy firsthand. “Our men and women in uniform deserve every tool available to heal and stay in the fight,” Luttrell stated, reinforcing the bipartisan support for this initiative.
On 18 April, Luttrell stood alongside Donald Trump as the former president signed an executive order aimed at accelerating research into psychedelics, primarily for veterans. “The suicide epidemic among veterans is a national tragedy,” Trump remarked, drawing attention to the alarming statistics that reveal veterans are more likely to die by suicide than in combat.
The Historical Context of PTSD Treatment
Historically, the treatment of PTSD within the military has evolved significantly. During World War II, soldiers were often sedated with barbiturates, which provided temporary respite but failed to address the underlying trauma. In contrast, MDMA and other psychedelics like psilocybin have shown promise in treating mental health issues profoundly and durably. However, there are concerns about the ethical implications of using these therapies to enhance combat readiness.
Dennis McKenna, an ethnobotanist, cautioned against the potential misuse of psychedelic therapy. “It would be completely cynical and cruel of the government to throw them back into combat,” he warned. The concern is that soldiers who undergo treatment might be returned to the battlefield without adequate emotional support, leading to further psychological distress. Doblin echoed this sentiment, noting that relapses can occur if individuals return to high-stress environments too quickly.
International Perspectives on Psychedelic Therapy
While the US military prepares for its studies, similar initiatives are emerging globally. In Ukraine, MAPS has trained therapists to facilitate MDMA-assisted therapy for soldiers amid a significant need for mental health support. Although MDMA therapy is not yet permitted in Ukraine, many troops have benefitted from legal ketamine treatments to alleviate PTSD symptoms. The situation underscores the urgent need for effective mental health interventions in military contexts worldwide.
Additionally, an upcoming MDMA-assisted group therapy study in Israel aims to address collective trauma among victims of the recent Hamas attacks. This study could become the largest clinical trial of its kind in Israel, involving both veterans and active service members. “We would like it to be a model to work with collective trauma that we can duplicate, not only in Israel but around the world,” said psychologist Keren Tzarfaty, underscoring the potential for international collaboration in addressing military-related mental health issues.
Why it Matters
The implementation of MDMA-assisted therapy for US soldiers represents a pivotal moment in addressing the mental health crisis affecting military personnel. With bipartisan support and a commitment to innovative treatments, this initiative could not only transform the lives of countless service members but also challenge long-standing perceptions of how we treat trauma. As the military grapples with the realities of modern warfare and its psychological toll, embracing new therapeutic approaches could pave the way for a more compassionate and effective system of care for those who serve.
